Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study (Q33347651)

26 July 2017

title

Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study (English)

1 reference

26 July 2017

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0090-8258(03)00079-9

27 December 2023

author name string

Peter G. Rose

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12713990

27 December 2023

John A. Blessing

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12713990

27 December 2023

Richard E. Buller

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12713990

27 December 2023

Robert S. Mannel

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12713990

27 December 2023

Kenneth D. Webster

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12713990

27 December 2023

language of work or name

English

0 references

publication date

1 May 2003

1 reference

full work available at URL

26 July 2017

https://api.elsevier.com/content/article/PII:S0090825803000799?httpAccept=text/xml

1 reference

DOI

https://api.crossref.org/works/10.1016/S0090-8258(03)00079-9

https://api.elsevier.com/content/article/PII:S0090825803000799?httpAccept=text/plain

27 December 2023

1 reference

DOI

https://api.crossref.org/works/10.1016/S0090-8258(03)00079-9

27 December 2023

1 reference

26 July 2017

volume

89

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

267-270

1 reference

The effect of mass screening on incidence and mortality of squamous and adenocarcinoma of cervix uteri

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900079-9

7 January 2021

The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900079-9

7 January 2021

Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900079-9

7 January 2021

A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900079-9

7 January 2021

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900079-9

7 January 2021

Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900079-9

7 January 2021

Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900079-9

7 January 2021

Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900079-9

7 January 2021

Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900079-9

7 January 2021

Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900079-9

7 January 2021

Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900079-9

7 January 2021

Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900079-9

7 January 2021

Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900079-9

7 January 2021

A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900079-9

7 January 2021

Cisplatin/etoposide chemotherapy for recurrent or primarily advanced cervical carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900079-9

7 January 2021

Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900079-9

7 January 2021

A phase I study of chronic daily dosing of oral etoposide in combination with cisplatin for patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900079-9

7 January 2021

Identifiers

DOI

1 reference

26 July 2017

1 reference